Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Schedule 1 - Genus PLC

18 Nov 2005 09:16

AIM18 November 2005 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: Genus plc COMPANY ADDRESS: Belvedere House Basing View Basingstoke Hampshire COMPANY POSTCODE: RG21 4HG COUNTRY OF INCORPORATION: United Kingdom COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: On 31 October 2005 Bridgewell Securities Limited, on behalf of Genus plc, made arecommended cash offer of 63.2p per Sygen Share for Sygen International plc.This transaction constitutes areverse takeover under the AIM rules. Genus is a quoted applicant seeking re-admission of its existing ordinaryshares and admission of its new ordinary shares to trading on AIM. Genus is a world leading bovine genetics company. At the heart of Genus' business lies a research and developmentprogramme with an annual cost of approximately £8 million per year. Laboratory bio-science is used to target andaugment traditional mating and selection programmes, testing about 400 new bulls each year. Genus appliesbiotechnology to the natural breeding of beef and dairy cattle, creating genetic improvement without the use ofgenetic modification and distributes frozen beef and dairy semen for both tropical and temperate agriculturesfrom its six studs located across four continents to farmers in approximately 70 countries. Sygen is a world leader in applying quantitative genetics and biotechnology to animal breeding. Sygen'stechnology, products and services enable pig and shrimp producers and farmers to enhance meat quality and improveefficiency in the production of meat animals. Sygen applies a combination of quantitative genetics andbiotechnology to animal breeding, which is applicable across several livestock species, and is currently appliedwith respect to pigs and shrimp. Sygen's products and services, which allow farmers and producers to createhigher quality and healthier non-GMO food products, add value throughout the global meat supply chain of farmers,producers, processors, distributors, retailers and consumers. The Directors of Genus consider that the Acquisition will provide the Enlarged Group with a considerableopportunity to maximise economies of scale, benefit from diversity of earnings in three complementary markets andcapitalise on the combined intellectual property of the Enlarged Group to generate greater growth potentialthrough the integration of the research and development functions. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares): Re-admission of 38,215,024 existing ordinary shares of 10 pence each, and admission of a further 16,923,080 newordinary shares of 10 pence each placed at an issue price of 325 pence CAPITAL TO BE RAISED ON ADMISSION: £55 million FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS: John Eric Hawkins - (Chairman) Richard Kenneth Wood - (Chief Executive) David Peter Timmins - (Group Finance Director) Edwin William White - (Senior Non-Executive Director) John Graham Worby - (Non-Executive Director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Before Admission: National Farmers Union - 13.46% Jupiter Asset Management - 8.94% M&G Investment Management - 3.45% F&C Asset Management - 3.03% After Admission: National Farmers Union - 11.00% M&G Investment Management - 7.38% Jupiter Asset Management - 6.97% F&C Investment Management - 3.10% NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: n/a ANTICIPATED ACCOUNTING REFERENCE DATE: 31 March EXPECTED ADMISSION DATE: TBC NAME AND ADDRESS OF NOMINATED ADVISER: Bridgewell Securities Limited Old Change House 128 Queen Victoria Street London, EC4V 4BJ NAME AND ADDRESS OF BROKER: Panmure Gordon (Broking) Limited Moorgate Hall 155 Moorgate London EC2M 6XB DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: Copies of the company's Admission Document will be available free of charge at the offices of BridgewellSecurities Limited, Old Change House, 128 Queen Victoria Street, London EC4V 4BJ during normal business hours onany weekday (Saturdays, Sundays and public holidays excepted) until one month after the date of Admission. DATE OF NOTIFICATION: 18 November 2005 NEW/ UPDATE (see note): NEW This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.